- Home
- QIPT vs ADVM Comparison
QIPT vs ADVM Comparison
Compare QIPT & ADVM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- QIPT
- ADVM
- Stock Information
- Founded
- QIPT 1993
- ADVM 2006
- Country
- QIPT United States
- ADVM United States
- Employees
- QIPT N/A
- ADVM N/A
- Industry
- QIPT
- ADVM Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- QIPT
- ADVM Health Care
- Exchange
- QIPT Nasdaq
- ADVM Nasdaq
- Market Cap
- QIPT 92.2M
- ADVM 59.5M
- IPO Year
- QIPT N/A
- ADVM 2014
- Fundamental
- Price
- QIPT $2.18
- ADVM $2.81
- Analyst Decision
- QIPT Strong Buy
- ADVM Strong Buy
- Analyst Count
- QIPT 2
- ADVM 5
- Target Price
- QIPT $6.50
- ADVM $26.60
- AVG Volume (30 Days)
- QIPT 98.5K
- ADVM 517.4K
- Earning Date
- QIPT 05-12-2025
- ADVM 05-20-2025
- Dividend Yield
- QIPT N/A
- ADVM N/A
- EPS Growth
- QIPT N/A
- ADVM N/A
- EPS
- QIPT N/A
- ADVM N/A
- Revenue
- QIPT $244,723,000.00
- ADVM $1,000,000.00
- Revenue This Year
- QIPT $3.35
- ADVM N/A
- Revenue Next Year
- QIPT $5.39
- ADVM $42.58
- P/E Ratio
- QIPT N/A
- ADVM N/A
- Revenue Growth
- QIPT 3.82
- ADVM N/A
- 52 Week Low
- QIPT $1.86
- ADVM $2.64
- 52 Week High
- QIPT $4.17
- ADVM $10.84
- Technical
- Relative Strength Index (RSI)
- QIPT 51.50
- ADVM 38.23
- Support Level
- QIPT $2.07
- ADVM $2.64
- Resistance Level
- QIPT $2.25
- ADVM $3.64
- Average True Range (ATR)
- QIPT 0.08
- ADVM 0.32
- MACD
- QIPT 0.02
- ADVM 0.04
- Stochastic Oscillator
- QIPT 72.55
- ADVM 17.00
About QIPT Quipt Home Medical Corp.
Quipt Home Medical Corp provides in-home monitoring equipment, supplies, and services to patients. The Company operates in one business segment, which is the sale and rental of medical equipment and related devices. The company's services consist of Daily and Ambulatory Aides, Power Mobility, INR Self-Testing, Respiratory Equipment Rental, Home ventilation, Oxygen Therapy, and Sleep Apnea and PAP Treatment.
About ADVM Adverum Biotechnologies Inc.
Adverum Biotechnologies Inc is a clinical-stage company that aims to establish gene therapy as a new standard of care for prevalent ocular diseases. It develops gene therapy product candidates intended to provide durable efficacy by inducing sustained expression of a therapeutic protein. Its product candidate, ixoberogene soroparvovec (Ixo-vec), is a single, in-office intravitreal (IVT) injection gene therapy product designed to deliver long-term durable therapeutic levels of aflibercept associated with a robust, sustained treatment response, reducing the treatment burden and fluctuations in macular fluid associated with bolus anti-vascular endothelial growth factor (VEGF) IVT injections.